FIELD: immunology.
SUBSTANCE: disclosed is an antibody or antigen-binding fragment thereof against GITR, a nucleic acid, an expression vector, a method for producing a host cell, a host cell. Also disclosed is a method of producing an antibody or antigen-binding fragment thereof, pharmaceutical compositions. Invention also discloses a method of inhibiting GITR biological activity, a method of treating, use of an antibody or its antigen-binding fragment.
EFFECT: present invention can find further application in therapy of cancer mediated by GITR.
60 cl, 33 dwg, 10 tbl, 23 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| IMMUNOCYTOKIN INCLUDING A HETERODIMERIC PROTEIN COMPLEX BASED ON ОСНОВЕ IL-15/IL-15Rα AND ITS APPLICATION | 2019 |
|
RU2753282C2 |
| MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, WHICH SPECIFICALLY BINDS TO BCMA, AND USE THEREOF | 2022 |
|
RU2820350C2 |
| ISOLATED BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS TO CD47 AND PD-L1 | 2021 |
|
RU2815823C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| DIVALENT BISPECIFIC CHIMERIC ANTIBODY COMPRISING HETERODIMER BASED ON MHC OR MHC-LIKE PROTEINS | 2021 |
|
RU2820683C2 |
| ANTIBODIES WHICH BIND TO SORTILIN AND INHIBIT THE BINDING OF PROGRANULIN | 2016 |
|
RU2735639C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
